Diagnostic Healthcare Solutions Company Developing New Test Designed to Measure Neutralizing Antibodies of Deadly Opioid Fentanyl

SAN DIEGO, CA, Jan. 17, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has filed a provisional patent application with […]

AXIM Biotechnologies, a leading healthcare solutions company, is making significant strides in the fight against the deadly opioid, Fentanyl. The company has recently developed a new test that is designed to measure neutralizing antibodies of this potent drug, which has been responsible for countless overdoses and deaths across the globe.

This innovative test has the potential to revolutionize the way Fentanyl is detected and treated, offering healthcare professionals a powerful tool in combating the opioid crisis. By accurately measuring neutralizing antibodies, the test can provide critical information about an individual’s susceptibility to Fentanyl overdose and help guide personalized treatment plans.

AXIM Biotechnologies’ decision to file a provisional patent application for this groundbreaking test demonstrates their commitment to advancing healthcare solutions and saving lives. The company’s dedication to research and development in this crucial area highlights their leadership in the diagnostic healthcare industry.

Impact on Individuals:

For individuals struggling with opioid addiction or at risk of Fentanyl overdose, the development of this new test could be life-changing. By providing valuable insights into an individual’s immune response to Fentanyl, the test could help healthcare providers tailor treatment plans to better meet each patient’s needs. This personalized approach to care has the potential to improve outcomes and save lives.

Impact on the World:

The global impact of AXIM Biotechnologies’ new Fentanyl test is immense. As the opioid crisis continues to ravage communities around the world, a diagnostic tool that can accurately measure neutralizing antibodies of Fentanyl could be a game-changer. By enabling early detection and intervention, this test has the potential to reduce overdose deaths, lower healthcare costs, and ultimately help stem the tide of the opioid epidemic.

Conclusion:

AXIM Biotechnologies’ development of a new test designed to measure neutralizing antibodies of Fentanyl represents a significant advancement in the fight against the opioid crisis. With the potential to improve individual treatment outcomes and have a positive global impact on public health, this innovative test has the power to save lives and change the way we approach Fentanyl overdose prevention. As AXIM Biotechnologies continues to lead the way in healthcare solutions development, the future looks brighter for those affected by opioid addiction.